Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Under $0.01 (..subpenny..) stocks -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (689)	3/21/2021 12:47:20 AM
From: Benny-Rubin	Respond to of 733

Hi Gary,thank you for the message.I know EWLL from several years back but never bought it but now I will put her back on my screen and keep an eye on it. The post you answered on my TSOI posting soared to .17 last month and now has settled in the .10 area. Company is waiting on word from the FDA on their JediCell and maybe we get an answer this week. Their Quadramune is in Phase 2 and StemVacs in Phase 1. In June 2019 the Company was on their last leg trading 0004 and its just amazing how the CEO got out of the hole. Their Lung Cancer drugs has shown some amazing possitive effects on Covid19 hence the FDA is allowing this Company trials with anywhere from 500 to 1200 to participate SI used to be a great site for penny stocks and its too bad nobody kept that alive.

To: Gary Mohilner who wrote (689)	3/23/2021 10:13:01 AM
From: Benny-Rubin	Respond to of 733

$TSOI has huge news today on a cell they invented, Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood VesselsNovel Strategy Demonstrates Potent Results in Animal Model of Lung Cancer through Fusing StemVacs-V™ Immunotherapy with In-Vitro Generated Cancer Blood Vessels ELK CITY, Idaho, March 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These data are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. "Killing malignant blood vessels is the basis for Avastin, an antibody-based drug which created 7 billion in revenue last year.1 Another company, Batu Biologics, previously demonstrated vaccination against cancer blood vessels is safe and was cleared by the FDA for clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company. "The approach developed by our Company is completely unique because it merges the potent antigen presenting capabilities of StemVacs-V together with the reproducibility and consistency of iPSC generated tumor-like endothelial cells." StemVacs-V™ is comprised of "cancer resistant" dendritic cells which are developed from an engineered iPSC cell line. The novel chimeric cell product is generated by fusing StemVacs-V with iPSC derived endothelial cells which are cultured in a manner to make them replicate cancer stem cells. Proof of selective killing of cancer blood vessels was obtained by demonstration of immune response to proteins found only on cancer blood vessels. "Numerous companies such as Fate Therapeutics, NantKwest, and Century Therapeutics have all achieved significant valuations through pioneering novel uses of iPSC derived immune cells," said Famela Ramos, Vice President of Business Development. "To our knowledge we are the first company to use iPSC derived cells to stimulate naturally occurring immunity to kill what some call the 'Achilles Heel' of cancer." "Generation of a new cell that didn't previously exist is a significant milestone for our Company. We believe the current animal studies in lung cancer can be extrapolated to other cancers, since no cancer can grow more than 2 millimeters without creating new blood vessels," said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "By selectively killing cancer blood vessels the problem of mutations is solved since cancer blood vessels are not generated from tumor tissue and they do not mutate. Furthermore, since blood vessels are in direct contact with the blood and immune cells that travel through the blood, it is substantially easier for the immune system to kill malignant vessels as opposed to tumors."